• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Clinical Breakpoint Tables

Clinical Breakpoint Tables Breakpoints are part of a system for categorizing microorganisms as: Susceptible (S) Susceptible, increased exposure (I) Resistant (R) To antimicrobial agents approved for use in the treatment of infectious diseases. Information of the structure of the tables and how they…

Get to know more

Setting Breakpoints

Setting Breakpoints Breakpoints for phenotypic antimicrobial susceptibility testing have been determined by breakpoint committees and as part of regulatory processes for the approval of new drugs since the 1970s. Knowledge of dosage, modes of administration, target infections and clinical outcome…

Get to know more

General consultation on colistin breakpoints

EUCAST is proposing to change colistin breakpoints to breakpoints in brackets . The consultation is open for comments between 6 October - 15 November. In breakpoint table v 12.0 (2022), EUCAST aims to introduce brackets for colistin breakpoints. The same model has been used previously for…

Get to know more

When there are no breakpoints!

The first and very important question is, when are there no breakpoints in the EUCAST breakpoint tables? Look for guidance on the interpretation of test results in breakpoint tables , expert rules and in EUCAST advice on expected phenotypes . In breakpoint tables guidance can be in the form of…

Get to know more

Aztreonam-avibactam and cefepime-enmetazobactam breakpoints published

MIC and zone diameter breakpoints for aztreonam-avibactam and cefepime-enmetazobactam are now available as addenda to the clinical breakpoint table 14.0. The breakpoints will be integrated in the regular breakpoint table 15.0, 1 Jan, 2025.

Get to know more

Clinical breakpoint table

Clinical breakpoint table (Yeast and moulds) Breakpoints and methods for susceptibility testing of yeasts, moulds and dermatophytes are developed and validated by the EUCAST subcommittee on AFST. Document Description Clinical breakpoints for fungi v. 12.0 PDF file for printing; valid from 26 June,…

Get to know more

Document Archive

Document Archive Breakpoint tables for fungi QC tables Methodology Rationale documents Clinical breakpoints for fungi (v 11.0) - pdf file for printing (until 26 June, 2025) Clinical breakpoints for fungi (v 11.0) - excel file for screen (until 26 June, 2025) Clinical breakpoints for fungi (v 10.0) -…

Get to know more

Breakpoints in brackets

EUCAST introduced breakpoints in brackets in 2020. In breakpoint table 12.0 (2022) there are breakpoints in brackets for aminoglycosides, colistin and for clindamycin for Bacteroides spp. A guidance document describes how to interpret and report breakpoints in brackets.

Get to know more

What to do when there are no breakpoints?

What to do when there are no breakpoints? Not every agent and/or species have breakpoints in EUCAST breakpoint tables. For some there may be PK/PD breakpoints, for others MIC distributions to guide recommendations. In this guidance document EUCAST gives advice on how to deal with uncommon species or…

Get to know more

Mycobacteria (AMST)

Mycobacteria (AMST) The EUCAST AMST develops breakpoints and methods for antimicrobial susceptibility testing of mycobacteria. Clinical breakpoints for Mycobacteria are part of the regular EUCAST breakpoint table for bacteria. For MIC distributions for Mycobacterium tuberculosis and other…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here